Connect with us

Hi, what are you looking for?

Stock

Biogen to start shipping Alzheimer’s drug in about two weeks

World57 minutes ago (Jun 08, 2021 11:36AM ET)

(C) Reuters. FILE PHOTO: A sign marks a Biogen facility, some of whose employees have tested positive for the coronavirus after attending a meeting in Boston, in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder/File Photo

(Reuters) -Biogen Inc said on Tuesday it expects to begin shipping its newly approved Alzheimer’s drug Aduhelm in about two weeks and has prepared more than 900 healthcare centers for the intravenous infusion treatment.

The U.S. Food and Drug Administration on Monday approved Aduhelm as the first treatment to target a likely underlying cause of Alzheimer’s disease, sticky deposits of a protein called amyloid-beta.

Biogen (NASDAQ:BIIB) Chief Executive Officer Michel Vounatsos said on a call with analysts that the sites include clinical trial centers with currently confirmed amyloid-beta positive patients, as well as other locations with infrastructure to diagnose and treat patients.

The company priced the drug at $56,000 per year and patients who are prescribed it need to undergo additional testing in the form of either a Cerebrospinal Fluid (CSF) test, or a PET scan to confirm the presence of amyloid-beta in the brain.

Biogen CFO Michael McDonnell said on the call there are about one to two million Americans who have been diagnosed with mild dementia or cognitive impairment, who would be amyloid-beta positive if tested.

The need for PET or CSF tests and the limited availability of specialists to oversee patients taking the drug could limit Aduhelm’s use in these patients, McDonnell said.

“We believe the majority of diagnosed patients are not currently under the care of a specialist, and as a result we expect gradual uptake over time,” he added.

Revenue from Aduhelm could start ramping up in 2022 and beyond, but could be low in 2021 due to the need for sites to prepare to diagnose and treat patients, and the time that it will take to secure insurance coverage for the drug, McDonnell said.

Guggenheim analysts on Monday estimated sales from the drug could be over $1.3 billion in 2022. Biogen shares were down about 3% at $384.87.

Biogen to start shipping Alzheimer’s drug in about two weeks

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

World News

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered...

World News

George Soros and Bill Gates are part of a consortium acquiring a British developer of rapid-testing technology, including for Covid-19 and tropical diseases,...

Tech

If you parked your car in one of the thousands of parking spots across Calgary, there’s a good chance you paid the Calgary Parking...

World News

Every gambler has their own way. Some people like playing poker, whereas others enjoy the excitement of rotating the wheel. Some people prefer...

Disclaimer: Yourmorningvoice.com it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. Copyright © 2021 Your Morning Voice. All Rights Reserved